Watch on YouTube After another record year for human challenge specialist Hvivo, chief executive Mo Khan talks us through the building blocks he’s putting in place to take the company to its longer-term target of £100m of sales by 2028. 0:30 Highlights of 2023 results, including record revenues and profitability, and Ebitda margins ahead of guidance. 1:30 Headwinds from MHRA review delays offset by client funding for new Canary Wharf facility. 2:20 What’s driving strong cash generation, and plans for regular shareholder returns. 3:40 Progress at the new Canary Wharf facility and government backing for a life science hub in the area. 6:40 How 2024 is shaping up, and how an increasingly diversified client base is improving resilience. 8:42 How the business is going to reach its longer term £200m sales target, including more human challenge models and M&A. 10:20 The value of recent attendance of the World Vaccine Congress Washington.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related